Versanis Bio

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

Growth in pharma’s pipeline picked up again last year but oncology’s contribution to the whole slackened as companies appeared to spread their R&D bets more broadly. So suggest the latest data from Ci

Deal volume was down last year both in M&A and alliances, but valuations rose. Early in 2023, Pfizer Inc. set the tone for a year of moving on from the COVID-19 pandemic by agreeing to pay $43bn for